Subject category:
Strategy and General Management
Published by:
Aalto University School of Economics (formerly HSE)
Length: 12 pages
Data source: Field research
Share a link:
https://casecent.re/p/21268
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
Orion Group, a Finnish pharmaceuticals company founded in 1917 consisted of six divisions. Two divisions belong to Orion Pharma; Orion-Farmos was the largest Finnish manufacturer and marketer of pharmaceuticals with a 27 per cent domestic market share, whereas Orion Pharma International concentrated on the export of pharmaceuticals, bulk drug substances and international operations. The products of Orion Pharma International were marketed through subsidiaries and a network of representatives. Orion has been developing a new drug, recosderine, and in 1994 at the final phase of the development, the company has to decide between two options, whether it should proceed with the project and later conclude marketing agreements with another company, or obtain a partner or partners for licensing.
About
Abstract
Orion Group, a Finnish pharmaceuticals company founded in 1917 consisted of six divisions. Two divisions belong to Orion Pharma; Orion-Farmos was the largest Finnish manufacturer and marketer of pharmaceuticals with a 27 per cent domestic market share, whereas Orion Pharma International concentrated on the export of pharmaceuticals, bulk drug substances and international operations. The products of Orion Pharma International were marketed through subsidiaries and a network of representatives. Orion has been developing a new drug, recosderine, and in 1994 at the final phase of the development, the company has to decide between two options, whether it should proceed with the project and later conclude marketing agreements with another company, or obtain a partner or partners for licensing.